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1. Introduction 
Abnormal development of the kidneys and the urinary tract, genetic factors, acquired  
disease during infancy and childhood, wrong dietary habits and environmental factors  may 
produce renal damage and cause renal insufficiency which may become clinically evident in 
adulthood. Prevention of renal insufficiency relies on early recognition of risk factors 
recognizable in childhood.   
2. Risk factors for kidney disease  
The incidence and progression of renal injury vary substantially among individuals who are 
at risk for kidney disease. Variability of risk for the occurrence and progression of Chronic 
Kidney Disease (CKD) suggests that biologically relevant characteristics may influence the 
occurrence or course of the renal disease. Prediction of increased risk of occurrence or 
progression of CKD may enable clinicians to identify individuals who may benefit from 
closer supervision of care or more intensive disease modifying interventions. Risk factors 
can be used to define at risk population that can be targeted for education and early 
intervention programs. These factors include familiarity of CKD, genetic factors, nephron 
number, low birth weight, perinatal programming, nutritional setting, hypertension and 
congenital abnormalities of the kidney and urinary tract (CAKUT) (Table 1). 
 
Risk factors for Chronic Kidney Disease detectable in childhood 
Family history of hypertension and kidney disease 
Low birth weight 
Perinatal kidney injury 
Congenital injury 
Hematuria and/or proteinuria 
Urinary tract infection 
High blood pressure 
Overweight 
Table 1. 
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2.1 Familiarity of CKD 
A family history of kidney disease (FAM)  has been associated with an increased risk of end 
stage renal disease (ESRD). In a recent report FAM was identified as an independent risk 
factor for ESRD [1]. In 1998 Lei at al in large population case-control study found a 
correlation between FAM and ESRD, especially in patients with a strong FAM with an odds 
ratio of 7.4.[2]. In the same year Freedman et al. found a high prevalence (20%) of FAM in 
dialysis patients. The prevalence decreased with age, was higher among African-Americans 
than Caucasians [3].  Satko et al documented a three- to nine-fold greater risk of ESRD in 
individuals with a FAM of ESRD. He noted a marked racial variation in the familial 
aggregation of kidney disease, with high rates in African American [4]. Other authors 
documented a stronger association in blacks than whites, indicating specific ethnic 
differences [5-6]. Recently in USA it has been proposed the ESRD Networks Family History 
Project as a national CKD surveillance system for patients with stage 5 CKD to identify 
relatives of incident patients with ESRD who are 2 to 3 times as likely to have ESRD [7].   
2.2 Genetic factors 
It is well known that genetic factors play a crucial role in CKD and ESRD [8] More recently, 
genome-wide association studies have yielded highly promising results suggesting a 
number of potential candidate genes and genomic regions that may contribute to the 
pathogenesis of CKD [8].  For example, common variants in the UMOD and PRKAG2 genes 
are associated with risk of chronic kidney disease [9]. Genome-wide association studies of 
CKD are beginning to define the genomic architecture of kidney disease and will impact our 
understanding of how genetic variation influences susceptibility to this condition. 
The expression of genes is defined by their epigenetic state; prenatal factors may produce 
stable changes in expression of genes as documented in several studies. DNA methylation 
[10], oxidative stress in response to low protein diet in pregnancy [11], telomere length [12] 
which is regulated by telomerase enzymatic activity during fetal life have been implicated in 
fetal renal development and disesase, excess glucocorticoids in early life can permanently 
alter tissue glucocorticoid signalling. All these studies show that the mechanism involved in 
developmental programming are likely epigenetic rather than due to DNA sequence 
mutations. It is important to note that changes produced by epigenetic factors, differently 
from genetic changes, are potentially reversible. 
2.3 Nephron number 
The number of nephrons in humans ranges from 250.000 to 2.5 million with an average of 
about 1 million per kidney; this high variability is due to various causes. Nephrogenesis 
ends at 36 weeks of gestation, for this reason premature newborns may have a reduced 
nephron number; the same condition is observed in patients with kidney disease and in 
older patients due to age–related glomerulosclerosis. In the  last 20 years many authors 
analyzed the association between nephron number and onset of renal disease later in life; 
most of these studies have been conducted in animals since it is difficult to determinate the 
number of glomeruli as measure of nephrons’  number in humans. Nyengaard and Bendtsen 
performed in 1992 the first study that calculated the number of glomeruli in the kidneys of 37 
Danes obtained at autopsy; they found a significant negative correlation between  glomerular 
number and age [13]. Successively Keller et al. documented a significant reduced number of 
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glomeruli in patients with hypertension compared to those who were normotensive [14]. More 
recently Zhang et al have documented a wide 4.5-fold variability in the number of glomeruli in 
children  younger than 3  months ranging from 246,181 to 1,106,062 [15]. 
2.4 Prematurity and low birth weight  
Low birth weight (LBW) is defined by the World Health Organization as a birth weight of 
<2500 g.  Intrauterine growth retardation (IUGR) is  defined as weight below the tenth decile 
for birth weight. 
 Fetal growth is conditioned by multiple factors which include the composition of maternal 
body,  alimentary habits during pregnancy, transport of nutrients through the placenta and 
others. The final consequence of the alteration of this factors determinate a fetal-growth 
reduction. The IUGR can be related to maternal undernutrition and/or placental insufficiency 
[16]. Placental insufficiency, usually associated with preeclampsia and maternal cardiovascular 
risk factors, is due to poor placentation. Maternal malnutrition is often related to wromg 
dietaty composition more than total calorie intake. In rats Langley-Evans et al have 
demonstrated that even short periods of maternal protein restriction during gestation in rats 
are associated with LBW and subsequent hypertension [17]. In humans, increased  protein 
turnover at 18 weeks of gestation is associated with increased length of babies at birth [18]. 
In humans, the causes of LBW are multifactorial: demographic factors, socio-economics 
status, poor maternal weight especially during pregnancy, shorter maternal height, maternal 
gestational weight gain below 7 kg, maternal hypertension, chronic infections, glucose 
intolerance or DM during pregnancy, maternal smoking or alcohol abuse, genetics, etc. 
Irving et al demonstrated that premature children, independently of birth weight, have an 
high risk of cardiovascular disease in adult age, thus making it very difficult to separate the 
effects of gestational age and birth weight [19]. However, the growth retardation for a given 
gestational age has greater relevance than the effect of prematurity on subsequent 
cardiovascular disease in adult age, as was demonstrated by Whincup et al [20]. The 
correlation between low birth weight  and number of nephrons was reported by Ma˜ nalich et 
al.; they observed a mean reduction of 20% of the nephrons in children with LBW. [21]. The 
same observations was obtained by Hughson et al who documented that LBW is accompanied 
by fewer large-volume nephrons than in individuals with normal birth weights [22]. 
Multiple animal models have demonstrated the association of LBW with later development 
of hypertension. The link between adult hypertension and LBW in these animal models 
appears to be mediated by a congenital nephron deficit showed by Vehaskari et al [23]. In 
humans many studies have reported higher blood pressures in those who had been of LBW. 
Barker et al first reported the association between hypertension in adult life and birth 
weight [24]. A study in Swedish children by Nilsson et al found a significant relation 
between birth weight and systolic arterial pressure [25]. Similar observations was done by 
Huxley et al [26]. In several studies, the relationship was more significant in girls than boys 
[27] and in woman than man [28]. The relationship between birth weight and blood pressure 
is also increased by accelerated postnatal growth [29] . Hoy et al in 1999 reported an 
association between low birth weight and CKD, observing increased rates of 
microalbuminuria in Australian Aborigines, a population with high rates of low birth 
weight [30]. In the last years many studies have documented that low birth weights 
contribute to high rates of early-onset chronic renal failure in United States patients, in 
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ducth adolescents, and in young and adult Norwegians [31-34].  In a meta-analysis, White et 
al. found that the combined odds ratio (OR) for risk of albuminuria associated with low 
birth weight was 1.81 (1.19–2.77) and for ESRD 1.58 (1.33-1.88). They concluded that existing 
data indicate that low birth weight is associated with subsequent risk of CKD  [35]. Recently, 
Hodgin et al. described an association between focal segmental glomerular sclerosis (FSGS) 
and prematurity and very low birth weight [36].  
2.5 Perinatal programming 
The processes of development and maturation of organs occur continuously throughout the 
pre- and postnatal periods. Intrauterine growth is generally regulated by intrinsic growth 
potential, genetic endowment, and support of nutrients from the materno-uteroplacental 
unit. However, during the postnatal period growth may be affected by environmental 
conditions and genetic background. The environmental impact on a genetic program 
determine the renal perinatal programming of each individual. The term “fetal 
programming” describes the structural and functional adaptive phenomena in response to 
critical periods during fetal life and early postnatal growth. Perinatal programming may 
produce a reduced nephron number leading to the development of chronic kidney disease 
[37]. Several environmental stressors may act on specific genetic programming of low 
nephron number. The time at which an adverse factor is involved during gestation before 
completion of nephrogenesis may affect kidney growth [38]. A history of LBW and IUGR, 
vitamin A deficiency, urinary tract malformations, administration of nephrotoxic drugs may 
interact to increase potential nephron damage. Maternal nutrition may have an important 
influence on renal programming [39]. In rats, a restricted supply of nutrients to the 
mother during nephrogenesis contributed to a reduced number of glomeruli per kidney, 
activation of the renin-angiotensin system, glomerular enlargement, and hypertension in 
adult life [40]. 
2.6 Hypertension 
Maternal hypertension is a significant risk factor for LBW and is more prevalent among 
black than white women, making the population-attributable risk of LBW highest among 
babies of hypertensive black mothers [41]. Taittonen et al found that a history of mother’s 
high blood pressure during pregnancy predicted future blood pressure more eminently than 
birth weight [42]. 
Hypertension is one of the major causes of renal insufficiency in adults. It has been proven 
that children with higher blood pressure develop hypertension, cardiovascular diseases and 
renal failure as adults. The first study that found a correlation of adult blood pressure with 
childhood blood pressure was the Muscatine study in 1989 [43]. Successively the Bogalusa 
Heart study documented that childhood blood pressure predicts adult microalbuminuria in 
African Americans, but not in whites [44]. In the same group of patients it was found that 
diastolic blood pressure in children and increased blood pressure variability in children are 
significantly correlated with adult hypertension [45-47]. 
2.7 Obesity 
Obesity is a recognized risk factor for end-stage renal disease (ESRD) [48]. The increased 
blood pressure associated with obesity is accompanied by impaired pressure natriuresis. 
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The volume expansion is related to activation of the sympathetic nervous system and renin-
angiotensin system. Obesity also causes renal vasodilation and glomerular hyperfiltration as 
compensatory mechanisms. In the long-term, these changes, along with the increased 
systemic arterial pressure, causes glomerular injury. Moreover obesity causes an increase of 
urinary protein excretion and gradual loss of nephron function that worsens with time and 
exacerbates hypertension. Overweight and obesity are associated with the metabolic 
syndrome and  type II diabetes, a major cause of kidney disease; in obese patients renal 
failure progresses much more rapidly [49].  
2.8 CAKUT 
Congenital abnormalities of the kidney and urinary tract in most cases apparently are not 
associated with a reduced glomerular filtration rate (GFR) but the renal reserve may be 
reduced to the point that an increased demand by a growing body produces a drop in GFR.  
A recent review of Sanna-Cherchi et al evaluated the renal outcome in patients with CAKUT 
[50]. They found that patients with solitar kidney, usually considered to have good 
prognosis, have a higher risk for dialysis  with an HR of 2.43 compared to patients with 
hypodysplasia or multicystic kidney. These data are in contrast to precedent studies that 
found a good prognosis of renal function in patients with unilateral agenesis [51]. In the last 
years many authors have looked for a correlation of CAKUT with genetic disorders [52].  
2.9 Hematuria and proteinuria  
Iseki et al in 1996 in a community mass screening found that proteinuria was the most 
useful predictor of ESRD (adjusted odds ratio 14.9, 95% confidence interval 10.9 to 20.2), and 
the next most potent predictor was hematuria (adjusted odds ratio 2.30, 95% confidence 
interval 1.62 to 3.28) [53]. In a recent paper Vivante A et Al found an increase of incidence of 
ESRD in patients (aged 16 to 25 year) with persistent asymptomatic isolated microscopic 
hematuria [54]. In 2011 a meta-analysis found that albuminuria is a  risk factor for all-cause 
and cardiovascular mortality in high-risk populations [55].  
2.10 Urinary tract infections and vesico-ureteral reflux 
Vesicoureteral reflux (VUR) is a frequent condition  in pediatric patients. Approximately 
1/3 of patients who have had a urinary tract infection (UTI) have VUR and 9–20% of 
patients with prenatal hydronephrosis have VUR [56].  Children affected by VUR may 
develop reflux nephropathy (RN) and  some of them  chronic kidney  disease (CKD). In a 
recent review Brakeman identifies the principal risk factors of progression of VUR to CKD: 
reduced glomerular filtration rate (GFR), bilateral VUR and/or renal scarring, grade V VUR, 
proteinuria, and hypertension. [57]. Ardissino et al found an estimated risk of end stage 
renal disease (ESRD) of  56%  in italian children by age 20 years [58] 
3. Evolution of renal damage 
The pathogenesis of progressive renal functional deterioration is certainly multifactorial, 
and the decline in glomerular filtration rate varies in groups of patients with different 
nephropathies, but also in patients with the same disease. Some of these factors may be 
modifiable, particularly in children,  and therapeutic interventions may result in a reduced 
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rate of deterioration of renal function. The persistent deterioration of renal function may be 
a result of repeated and chronic insults to the renal parenchyma leading to permanent 
damage and/or to the adaptive hyperfiltration response of the kidney. The reduced 
glomerular filtration area due to congenital or acquired nephron deficit, according with the 
Brenner’s hypothesis of “glomerular hyperfiltration”, could expose to a higher risk of 
cardiovascular and renal disease in adulthood since the increased workload produces 
proteinuria with glomerulosclerosis, tubulointerstitial inflammation and fibrosis [59]. In 
addition to hyperfiltration and proteinuria, there is evidence that chronic renal hypoxia 
could be directly involved in the progression of CKD, particularly in progression of 
tubulointerstitial fibrosis. Chronic renal hypoxia could be elicited by several factors such as 
loss of peritubular capillaries (PTCs), decreased PTC flow, decreased nitric oxide production 
and/or bioavailability and activation of the renin-angiotensin system. With regard to this, 
Kang et al previously demonstrated that the inhibition of NOS accelerated renal damage in a 
remnant kidney model by eliciting PTC loss [60]. Recent evidence suggests that overweight 
and obesity play a role in renal-pressure natriuresis. Excessive weight gain increases renal 
tubular reabsorption and impairs pressure natriuresis, in part, through activation of the 
sympathetic and renin-angiotensin system as well as physical compression of the kidney. 
With prolonged obesity, there are also structural changes in the kidney (including 
enlargement of Bowman’s space, increased glomerular cell proliferation, increased 
mesangial matrix, and thicker basement membranes, increased expression of glomerular 
transforming growth factor) that eventually cause loss of nephron function, further 
impairment of pressure natriuresis, and further increases in arterial pressure [61].  Finally, a 
number of genetic factors (eg, single nucleotide polymorphisms and modifier genes) may 
influence the immune response, inflammation, fibrosis, and atherosclerosis, possibly 
contributing to accelerated progression of CKD [62]. With respect to specific genes, 
apolipoprotein E (ApoE) polymorphisms may alter the risk of atherosclerotic disease, and 
therefore progression of CKD. The ApoE epsilon-2 allele is associated with elevated 
lipoprotein and triglyceride levels, whereas the ApoE epsilon-4 allele is associated with 
elevated levels of high density lipoprotein and lower triglycerides. In a secondary analysis 
of the Atherosclerosis Risk in Communities Study of 14,520 patients with a median follow-
up of 14 years, individuals with an ApoE epsilon-4 allele (present in 30 percent) had a 15 
percent reduction in risk of progression of CKD compared to individuals with ApoE 
epsilon-3 allele (present in 90 percent). The risk with the ApoE epsilon-2 allele was not 
significantly different compared with ApoE epsilon-3 [63]. Gene expression profiles within 
the kidney may help identify molecular prognostic factors in chronic renal disease. In the 
future, genetic testing and molecular analysis of renal biopsy specimens (and/or urine) may 
provide useful prognostic information. 
The rate of progression to ESRD in childhood is inversely proportional to the baseline CrCl 
at presentation. In addition, genetic, familial, or ethnic predisposition may influence the rate 
of renal decline. As an example, African-Americans are more susceptible to CKD, and the 
rate of progression of CKD is higher among African-American males than other ethnic 
groups. The rate of progression of CKD is usually greatest during the two periods of rapid 
growth, infancy and puberty, when the sudden increase in body mass results in a rise in the 
filtration demands of the remaining nephrons [64]. Therefore children may have a normal 
glomerular filtration rate which sharply reduces in young adulthood. These events place 
increased demands upon the preexistent compromised kidney function. As a result, children 
with CKD should be closely monitored during these two periods for an accelerated 
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progression of CKD. In addition to the increase in body mass, hormonal changes during 
puberty may also contribute to the rapid decline in renal function seen in adolescence. 
4. Causes of renal injury and renal failure in children 
Genetic and environmental factors are traditionally considered causes of human disease. 
Many genetic disorders may cause renal disease in childhood or in adults (Table 2) but also 
prenatal factors may produce stable changes in expression of genes. Studies from diverse 
populations suggest that fetal programming may be the origin of several intrauterine events 
that ultimately manifests as overt disease such as hypertension, type 2 diabetes, obesity, and 
chronic kidney disease (CKD) [65]. 
 
GENETIC KIDNEY DISEASE 
Cystic disease 
Polycistic Disease (ARPKD, ADPKD) 
Tuberous Sclerosis 
Von Hippel Lindau Syndrome 
Glomerulocystic Disease 
Medullary Cystic Disease (Nephronophthisis) 
 
Glomerular Disease 
Alport Syndrome 
Family Focal Glomerulosclerosis 
Congenital Nephrotic Syndrome 
Nail-Patella Syndrome 
Denys-Dash Syndrome 
 
Tubular Disease 
Dent Syndrome 
Distal tubular acidosis 
Lowe's syndrome  
Fanconi Syndrome 
Gitelman syndrome 
Bartter syndrome 
Table 2. 
In addition to prenatal conditions, adverse postnatal events must be taken in consideration: 
infections, drugs, trauma, systemic diseases etc. In fact, CKD in children, which has a much 
lower prevalence than in adults,  is the result of a heterogeneous group of disorders (Figure 
1). Congenital disease accounts for almost 60 percent of CKD cases and includes obstructive 
uropathy, renal hypoplasia, and renal dysplasia. Glomerular disorders are the second 
largest cause of childhood CKD and are present in 7 to 17 percent of children with CKD. 
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Glomerular disease is more common in children greater than 12 years of age. Focal 
segmental glomerulosclerosis (FSGS) is the most common glomerular disorder occurring in 
9 percent of all CKD cases. Other causes account for approximately 25 percent of cases. In 18 
percent of all cases of CKD, the underlying primary diagnosis is not identified (15 percent) 
or is unknown (3 percent). Other more uncommon causes of CKD in children include 
hemolytic-uremic syndrome, genetic disorders (eg, cystinosis, oxalosis, and hereditary 
nephritis), and interstitial nephritis. 
 
Fig. 1. FSGS: focal segmental glomerulosclerosis; GN: glomerulonephritis; Structural: 
structural anomalies of the kidney and urinary tract. 
Adapted from: NAPRTCS: 2007 Annual Report, Rockville, MD, EMMES, 2007. Available at 
https://web.emmes.com/study/ped/announce.htm.  
5. Prevention of renal diseases and kidney injury 
Preventing renal impairment is an urgent challenge for medical practitioners. Several 
studies indicate that earlier stages of CKD can be detected through laboratory testing, and 
that early therapeutic interventions in the course of CKD are effective in slowing or 
preventing the progression toward ESRD and its associated complications [66]. Pediatricians 
and General Practioners should closely follow these infants, Health Care and Education 
providers should prioritize programs to stress the importance of preventive care and 
continuity of care especially for children of mothers with evidence of low propensity toward 
health promotion. 
The NKF-K/DOQI guidelines for CKD, reviewed in Kidney Disease Improving Global 
Outcomes (KDIGO), recommend that all individuals should be assessed, as routine health 
examinations, to determine the increased risk for developing CKD. Patients who are at risk 
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for developing CKD should be screened for hematuria with a urinalysis and with a urine 
test for proteinuria and a blood test for creatinine to estimate GFR. Depending upon the 
presence of particular risk factors, additional testing such as renal ultrasonography may be 
required, for example in patients with a family history of polycystic kidney disease. A 
formidable task for paediatricians is to prevent renal diseases that may develop in adult life. 
In order to achieve such goal, they should identify children at risk, counsel families to 
minimize any further renal risk factors such as smoking, obesity, and hypertension, and, in 
some cases together with a nephrologist, to institute pharmacologic therapy [67].  
Strict blood pressure control has been shown to slow the progression of kidney disease and 
reduce the risk of cardiovascular disease. The National High Blood Pressure Education 
Program Working Group (NHBPEP) established guidelines for the definition of normal and 
elevated blood pressures (BP) in children by developing blood pressure percentiles based on 
gender, age, and height [68]. Hypertension (HTN) is defined as either systolic and/or 
diastolic BP ≥95th percentile measured upon three or more occasions. Therapy includes both 
nonpharmacologic and pharmacologic interventions. Treatment should be initiated with 
conservative measures such as weight reduction, exercise, and dietary salt reduction. 
Pharmacologic therapy may be started in non responders;  ACE inhibitors or angiotensin II 
receptor blockers (ARBs), that are the preferred antihypertensive agents as they reduce 
proteinuria and appear to be more beneficial in slowing the progression of CKD compared 
to other agents in patients with CKD [69-70].  
Additional interventions that have been studied in adults with CKD include dietary protein 
restriction, lipid lowering therapy, and correction of anemia. However, results are 
inconclusive with respect to the impact of these interventions upon delaying the progression 
of CKD. In children, data have not shown a benefit of a low protein diet upon the 
progression of kidney disease CKD [71]. The current consensus by pediatric nephrology 
experts is to provide children with CKD the age appropriate recommended daily allowance 
for protein. 
6. Treatment  
The management of patients with CKD varies upon the severity of CKD. In the early stage it 
is important to treat reversible kidney dysfunction and prevent or slow the progression of 
kidney disease. In advanced stages (Stage 3 to 5) the management is focused on preventing 
and treating the complications of CKD, that include disorders of fluid and electrolytes, renal 
osteodystrophy, anemia, hypertension, dyslipidemia, growth impairment. The most 
common conditions with potentially recoverable kidney function are primarily due to 
decreased kidney perfusion or to the administration of nephrotoxic agents. Kidney 
hypoperfusion is produced by systemic hypotension, volume depletion from vomiting, 
diarrhea, diuretic use, or bleeding, and the administration of drugs that lower the kidney 
perfusion (such as nonsteroidal anti-inflammatory drugs, angiotensin converting enzyme 
[ACE] inhibitors, angiotensin II receptor blockers [ARBs]). Common nephrotoxic drugs 
include nonsteroidal anti-inflammatory agents, diagnostic agents (eg, radiographic contrast 
materials), and others (eg, aminoglycosides, amphotericin B, cyclosporine, and tacrolimus). 
The administration of such drugs, therefore, should be avoided or used with caution in 
patients with underlying CKD, with the assistance of therapeutic drug level monitoring. [72]  
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6.1 CKD complications  
Major Problems in children with CKD  
• Water and sodium retection 
• Hyperkalemia 
• Metabolic acidosis 
• Mineral metabolism and bone disease 
• Anemia 
• Nutrition 
• Growth 
Table 3.  
6.1.1 Water and sodium retention 
It’s present as GFR becomes severely decreased (ie, stages 4 and 5 disease), and it may result 
in volume overload. In general, a combination of dietary sodium restriction and diuretic 
therapy may correct the increased water balance. Dietary sodium intake should be 
decreased to 2 to 3 g/day and diuretic therapy includes loop diuretics such as 
furosemide given at a dose of 0.5 to 2 mg/kg per day [73].  
6.1.2 Hyperkalemia  
Hyperkalemia develops primarily because of inadequate potassium excretion due to a 
reduced GFR. Other factors that can contribute to elevated potassium levels include a high 
dietary potassium intake, metabolic acidosis, hypoaldosteronism (due in some cases to 
administration of an ACE inhibitor or an ARB), or an impaired cellular uptake of potassium. 
Management to prevent hyperkalemia in children with CKD consists in low potassium diet, 
administration of a loop diuretic (eg, furosemide) to increase urinary potassium loss, 
correction of acidosis with oral sodium bicarbonate [73].  
6.1.3 Metabolic acidosis 
Metabolic acidosis is characteristically present when the estimated GFR is less than 30 
mL/min per 1.73 m2 (ie, stage 4 disease). Acidosis is associated with growth impairment 
because the body utilizes bone buffering to bind some of the excess hydrogen ions. Current 
guidelines by the K/DOQI working group are to maintain the serum bicarbonate level at or 
above 22 mEq/L . Sodium bicarbonate therapy is started at 1 to 2 mEq/kg per day in two to 
three divided doses, and the dose is titrated to the clinical target [74].  
6.1.4 Mineral metabolism and bone disease  
Alterations of mineral metabolism are an almost universal finding with progressive CKD 
due to abnormalities in the metabolism of calcium, phosphate, vitamin D, and parathyroid 
hormone (PTH) levels. If these abnormalities are not addressed, these changes result in 
kidney bone disease, referred to as renal osteodystrophy. The management and prevention 
of secondary hyperparathyroidism is complex and requires frequent monitoring and 
adjustment of therapy. The initial step is to correct phosphate retention by dietary restriction 
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usually combined with either calcium-containing phosphate binders and/or sevelamer. The 
KDOQI guidelines recommend that treatment with calcitriol should be started when the 
serum 25-hydroxyvitamin D is <30 ng/mL (75 nmol/L), or when serum PTH is above the 
target range [75]. In adults, calcimimetics have been increasingly used to suppress PTH 
secretion and decrease the risk of hypercalcemia associated with calcitriol. These agents, 
which increase the sensitivity of the calcium-sensing receptor (CaSR) in the parathyroid 
gland to calcium, have not been adequately studied in the pediatric population.  
6.1.5 Anemia  
Anemia in CKD is due to reduced kidney erythropoietin production and generally develops 
when the GFR is below 30 mL/min per 1.73 m2. The treatment of anemia in children with 
CKD often includes iron supplementation and erythropoiesis stimulating agent (ESA). The 
K/DOQI guidelines recommend a target Hgb between 11 and 12 g/dL based upon consensus 
expert opinion. The initial ESA dose in older children not receiving dialysis is 80 to 120 u/kg 
per week, administered in two to three divided doses. Children younger than five years of age 
or children receiving dialysis frequently require higher doses (300 u/kg per week) [76-77].   
6.1.6 Nutrition 
Malnutrition is common in children with CKD because of poor appetite, decreased intestinal 
absorption of nutrients, and metabolic acidosis. Attention to nutrition is critical as it affects 
both the physical growth and neurocognitive development of children [78].  
6.1.7 Growth  
Growth failure has been long recognized in children with CKD. While the institution of 
recombinant human growth hormone (rHuGH) therapy can have a profound effect on the 
height velocity of children with CKD who are growing poorly, early recognition and 
management of malnutrition, renal osteodystrophy, acid-base abnormalities and electrolyte 
disturbances should take place prior to considering the institution of rHuGH. [79].  
6.1.8 Renal replacement therapy  
Once the estimated GFR declines to less than 30 mL/min per 1.73 m2 (stage 4 CKD), it is 
time to start preparing the child and the family for renal replacement therapy. The family 
should be provided with information related to preemptive kidney transplantation, 
peritoneal dialysis, and hemodialysis. As in adults, some form of renal replacement therapy 
will generally be needed when the GFR falls below 15 mL/min per 1.73 m2 (stage 5 CKD). 
However, renal replacement therapy is often initiated before children reach these levels.  
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